REG - Hikma Pharmaceutical - Notice of Results <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

03/03/2016 09:30

RNS Number : 9302Q
Hikma Pharmaceuticals Plc
03 March 2016
Notice of Results
LONDON, UK, 3 March, 2016 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, will announce its annual financial results for the year ended 31 December 2015 on Wednesday 16 March 2016. 
A presentation and webcast for analysts will be held at 9.30am GMT at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. 
To join via conference call please dial: +44 (0) 20 3003 2666 
UK TollFree Number: 0808 109 0700
The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16532/58467/Lobby/default.htm
Playback facility:
A playback of the conference call will be available up to 7 days after the presentation.
UK & International Number: +44 (0) 20 8196 1998
UK Toll-Free Number: 0800 633 8453
Replay PIN code: 8022823#
-Ends-
Enquiries
Hikma Pharmaceuticals PLC 

Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/+44 7776 477050
Zeena Murad, Investor Relations Manager
+44 (0)20 7399 2768/+44 7771 665277
FTI Consulting

Ben Atwell/Matthew Cole 
+44 (0)20 3727 1000
About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Branded", "Injectables" and "Generics", based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of US$1,489 million and profit attributable to shareholders of US$299 million.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORZMGGFLFGGVZG